These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23399652)

  • 81. Influence of Geography on Prostate Cancer Treatment.
    Tang C; Lei X; Smith GL; Pan HY; Hoffman KE; Kumar R; Chapin BF; Shih YT; Frank SJ; Smith BD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1286-1295. PubMed ID: 33316361
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey.
    Bukavina L; Tilburt JC; Konety B; Shah ND; Gross CP; Yu JB; Schumacher F; Kutikov A; Smaldone MC; Kim SP
    Eur Urol Focus; 2020 Mar; 6(2):273-279. PubMed ID: 30219709
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
    Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Trends in the use of androgen deprivation in prostate cancer.
    Salminen EK; Wickström JE; Vahlberg T; Duchesne GM
    Acta Oncol; 2004; 43(4):382-7. PubMed ID: 15303500
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
    Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
    J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer.
    Parikh RR; Byun J; Goyal S; Kim IY
    Prostate; 2017 May; 77(6):559-572. PubMed ID: 28093791
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
    Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Physician social networks and variation in prostate cancer treatment in three cities.
    Pollack CE; Weissman G; Bekelman J; Liao K; Armstrong K
    Health Serv Res; 2012 Feb; 47(1 Pt 2):380-403. PubMed ID: 22092259
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Medicare fee reductions and the overuse of intensity-modulated radiotherapy.
    Howard DH; Hockenberry J
    Health Serv Res; 2021 Aug; 56(4):626-634. PubMed ID: 33905136
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees.
    Marchetti KA; Oerline M; Hollenbeck BK; Kaufman SR; Skolarus TA; Shahinian VB; Caram MEV; Modi PK
    Urology; 2021 Sep; 155():77-82. PubMed ID: 33610652
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Documenting Horizontal Integration Among Urologists Who Treat Prostate Cancer.
    Mitchell JM; Gresenz CR
    Med Care Res Rev; 2022 Feb; 79(1):141-150. PubMed ID: 33331217
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II)--a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.
    De Bari B; Alongi F; Franco P; Ciammella P; Chekrine T; Livi L; Jereczek-Fossa BA; Filippi AR;
    Radiol Med; 2013 Oct; 118(7):1220-39. PubMed ID: 23716281
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Radical prostatectomy for prostate cancer, perioperative management by French urologists in 2018].
    Gas J; Dominique I; Mathieu R; Poinas G; Cuvelier G; Rebillard X; Corbel L;
    Prog Urol; 2020 Sep; 30(10):541-546. PubMed ID: 32646841
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Defining a standard set of patient-centered outcomes for men with localized prostate cancer.
    Martin NE; Massey L; Stowell C; Bangma C; Briganti A; Bill-Axelson A; Blute M; Catto J; Chen RC; D'Amico AV; Feick G; Fitzpatrick JM; Frank SJ; Froehner M; Frydenberg M; Glaser A; Graefen M; Hamstra D; Kibel A; Mendenhall N; Moretti K; Ramon J; Roos I; Sandler H; Sullivan FJ; Swanson D; Tewari A; Vickers A; Wiegel T; Huland H
    Eur Urol; 2015 Mar; 67(3):460-7. PubMed ID: 25234359
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.
    Ellis SD; Nielsen ME; Carpenter WR; Jackson GL; Wheeler SB; Liu H; Weinberger M
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):173-81. PubMed ID: 25849354
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Understanding Active Surveillance for Prostate Cancer.
    Lai LY; Shahinian VB; Oerline MK; Kaufman SR; Skolarus TA; Caram MEV; Hollenbeck BK
    JCO Oncol Pract; 2021 Nov; 17(11):e1678-e1687. PubMed ID: 33830822
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
    Faraj KS; Kaufman SR; Herrel LA; Maganty A; Oerline MK; Caram MEV; Shahinian VB; Hollenbeck BK
    Cancer; 2024 May; 130(9):1609-1617. PubMed ID: 38146764
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study.
    Aggarwal A; Lewis D; Sujenthiran A; Charman SC; Sullivan R; Payne H; Mason M; van der Meulen J
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1261-1270. PubMed ID: 28964586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.